Trial Profile
Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2009
Price :
$35
*
At a glance
- Drugs Exisulind (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Nov 2009 Additional lead trial investigator (Leibovich BC) identified as reported by ClinicalTrials.gov.
- 17 Nov 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
- 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.